Interim PET results according to the central review in the ITT population
| . | Obinutuzumab . | Rituximab . | ||||
|---|---|---|---|---|---|---|
| CHOP, n = 171 . | ACVBP, n = 165 . | All, n = 336 . | CHOP, n = 172 . | ACVBP, n = 162 . | All, n = 334 . | |
| PET2 | ||||||
| Negative, n (%) | 111 (64.9) | 111 (67.3) | 222 (66.1) | 103 (59.9) | 103 (63.6) | 206 (61.7) |
| Positive, n (%) | 43 (25.1) | 37 (22.4) | 80 (23.8) | 55 (32.0) | 41 (25.3) | 96 (28.7) |
| Not reviewed | 17 | 17 | 34 | 14 | 18 | 32 |
| PET4 | ||||||
| Negative, n (%) | 133 (77.8) | 127 (77.0) | 260 (77.4) | 123 (71.5) | 110 (67.9) | 233 (69.8) |
| Positive, n (%) | 18 (10.5) | 19 (11.5) | 37 (11.0) | 32 (18.6) | 24 (14.8) | 56 (16.8) |
| Not reviewed | 20 | 19 | 39 | 17 | 28 | 45 |
| . | Obinutuzumab . | Rituximab . | ||||
|---|---|---|---|---|---|---|
| CHOP, n = 171 . | ACVBP, n = 165 . | All, n = 336 . | CHOP, n = 172 . | ACVBP, n = 162 . | All, n = 334 . | |
| PET2 | ||||||
| Negative, n (%) | 111 (64.9) | 111 (67.3) | 222 (66.1) | 103 (59.9) | 103 (63.6) | 206 (61.7) |
| Positive, n (%) | 43 (25.1) | 37 (22.4) | 80 (23.8) | 55 (32.0) | 41 (25.3) | 96 (28.7) |
| Not reviewed | 17 | 17 | 34 | 14 | 18 | 32 |
| PET4 | ||||||
| Negative, n (%) | 133 (77.8) | 127 (77.0) | 260 (77.4) | 123 (71.5) | 110 (67.9) | 233 (69.8) |
| Positive, n (%) | 18 (10.5) | 19 (11.5) | 37 (11.0) | 32 (18.6) | 24 (14.8) | 56 (16.8) |
| Not reviewed | 20 | 19 | 39 | 17 | 28 | 45 |
See Table 1 for expansion of other abbreviations.